Modality
Vaccine
MOA
BETi
Target
PI3Kα
Pathway
Cell Cycle
FSGSNarcolepsyEoE
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
Dec 2020
→ Dec 2027
Phase 1Current
NCT03163476
2,964 pts·EoE
2023-10→2027-12·Terminated
NCT05385508
1,765 pts·FSGS
2020-12→TBD·Terminated
4,729 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-241.7y awayPh2 Data· EoE
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Termina…
P1/2
Termina…
Catalysts
Ph2 Data
2027-12-24 · 1.7y away
EoE
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03163476 | Phase 1/2 | EoE | Terminated | 2964 | UPDRS |
| NCT05385508 | Phase 1/2 | FSGS | Terminated | 1765 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα |